Organoplatinum anti-tumor compounds function as broad spectrum, highly effective anticancer drugs. However, the toxicity of these compounds has plagued their use from the outset. In an attempt to enhance the delivery and mitigate the side-effects associated with the use of these drugs, a wide variety of polymer-drug conjugates have been prepared and evaluated for antitumor activity. The advent of dendrimers, and polymers with well-defined size, shape, and surface functionality, has provided the opportunity for the development of organoplatinum antitumor agents of enhanced activity and diminished toxicity. A generation 4.5 PAMAM dendrimer (carboxylate surface) has been treated with diaquo(1,2-diaminocyclohexane)platinum(II) to generate a well-defined dendrimer-platinum conjugate containing forty (1,2-diaminocyclohexane) platinum(II) units coordinated to the dendrimer surface via carboxylate groups. This adduct is well-behaved, water-soluble, contains a high loading of platinum, and displays sustained release of active platinum species over a 24 hour period under physiological conditions. It seems to offer great potential as a new nanoscale multivalent organoplatinum antitumor agent.
- (carboxylate)(1,2-diaminocyclohexane) platinum(II) compounds
- Organoplatinum antitumor agents
- PAMAM dendrimers
- multivalent drugs
- nanoscale drug carriers
- time-release drug formulations